Endocrine Abstracts

Aim: In a previous study, we demonstrated elevated mean platelet volume in isolated hypogonadotrophic hypogonadism (IHH) is associated with high cardiovascular risk. Monocyte count/HDL-cholesterol ratio (MHR) is a new inflammatory marker showing cardiovascular risk. The purpose of this study is to evaluate (MHR) in men with hypogonadotrophic hypogonadism.

Method: This study includes 31 men with isolated hypogonadotrophic hypogonadism without previous treatment (mean age 22.5±7.2 year; BMI 21.6±4.9 kg/m²) and 44 healthy men who have similar age and BMI (mean age 22.9±6.4 years; BMI (19.5±3.2 kg/m²). HH was defined as total testosterone being below 229 ng/dl because of the absence or inadequacy of hypophyseal gonadotropins Hormonal biochemical and hematological parameters were measured by automatic analyzer after 12 h fasting.

Results: In our data, we detected statistically significant differences in total testosterone level (mean total testosterone levels 43.9±43.9 ng/dl in HH group vs 524.6±275.1 ng/dl in control group, respectively, P=0.000).

There was no statistically a significant difference between HH group and control group(mean HDL-C 49.3±16.6 mg/dl in HH group vs 46.7±8.3 mg/dl in control group, respectively, P=0.7), monocyte count (mean monocyte count 0.5±0.3/mm³ in HH group vs. 0.6±0.2/mm³ in control group, respectively, P=0.2) and MHR (mean MHR 0.015±0.014 in HH group vs 0.081±0.4 in control group, respectively, P=0.57). MHR also was not correlated with hematological parameters and total testosterone.

Conclusions: HH may not be a parameter that can be used for evaluation of monocyte count/HDL-cholesterol, cardiovascular risk in men.